Torrent, true to its tradition, barring a lull in the late nineties, has rapidly introduced a slew of new products. Alprax, an anxiolytic product, is Torrent's number one brand with turnover exceeding Rs.289 million (US$ 5.8 million) is also a market leader. The other Torrent brands, which figure in the top 200 Indian Brands, are Dilzem (Diltiazem), Domstal (Domperidone), Droxyl (Cefadroxyl) and Listril (Lisinopril).

In 2001-02, it launched 31 new products, notable among them being Moxif (Moxifloxacin), Lefra (Leflunomide), Nexpro (Esomeprazole), Adcef (Cefdinir), Feliz (Citalopram), Neasyn SR (Nicotinic acid) and Zaplon (Zaleplon), some of these are first time launches in the Indian market.

Torrent has made its remarkable presences in Antibacterial field by introducing Quintor (Ciprofloxacin), Uroflox (Norfloxacin), Droxyl (Cefadroxil), Moxif (Moxifloxacin). It is a leader in the range of cardiovascular products market including Dilzem (Diltiazem), Listril (Lisinopril), Nikoran (Nikorandil), Deplatt (Clopidogril). In Gastro intestinal range Torrent has its key products like Topcid (Famotidine), Omizac (Omeprazole), Ranitin (Ranitidine). Diclogesic (Diclofenac Sodium & Paracetamol) are the leading brands in the NSAID segment.